imiquimod has been researched along with tofacitinib in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Akiyama, T; Hashimoto, T; Sakai, K; Sanders, KM; Yosipovitch, G | 1 |
| Banfi, G; Bridgewood, C; Damiani, G; Dunsmuir, R; El-Sherbiny, YM; Khan, A; Loughenbury, P; Malagoli, P; McGonagle, D; Millner, PA; Pigatto, PDM; Rao, A; Rowe, H; Russell, T; Sharif, K; Timothy, J; Vadakekolathu, J; Watad, A; Zhou, Q | 1 |
3 other study(ies) available for imiquimod and tofacitinib
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Antipruritic Effects of Janus Kinase Inhibitor Tofacitinib in a Mouse Model of Psoriasis.
Topics: Animals; Antipruritics; Behavior, Animal; Disease Models, Animal; Imiquimod; Interleukin-22; Interleukin-23; Interleukins; Janus Kinase Inhibitors; Male; Mice, Inbred C57BL; Nerve Fibers; Piperidines; Pruritus; Psoriasis; Pyrimidines; Pyrroles; Skin | 2019 |
SARS-CoV-2 Infection Induces Psoriatic Arthritis Flares and Enthesis Resident Plasmacytoid Dendritic Cell Type-1 Interferon Inhibition by JAK Antagonism Offer Novel Spondyloarthritis Pathogenesis Insights.
Topics: Adjuvants, Immunologic; Adult; Aged; Arthritis, Psoriatic; Computational Biology; COVID-19; Cyclic Nucleotide Phosphodiesterases, Type 4; Dendritic Cells; Female; Gene Expression Regulation; Humans; Imiquimod; Interferon-alpha; Janus Kinases; Male; Middle Aged; NF-kappa B; Oligonucleotides; Phosphodiesterase 4 Inhibitors; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Signal Transduction; Toll-Like Receptor 7; Toll-Like Receptor 9; Transcriptome; Tumor Necrosis Factor-alpha | 2021 |